In 2026, the company completed the upgrade and transformation of its second-phase dust-free production line. The new production line strictly adheres to the EU EP Pharmacopoeia production standards, optimizes the purification process of small molecule peptides, and fully meets the latest EU food ingredient control regulations for heavy metals and microbial indicators. After this upgrade, all categories of peptide products can be directly cleared for import into 27 EU countries, significantly shortening the customs clearance cycle for European customers, reducing import compliance costs, further consolidating the supply capacity of peptide raw materials in the European region, and assisting cooperative customers in expanding local offline supermarket and health product factory channels.